Buy Bdenza : Enzalutamide 40 Mg Capsules 112’S Online

Description

Description: Bdenza is a medication manufactured by BDR Pharmaceuticals Int’l Pvt Ltd. It contains the active substance enzalutamide in each capsule. Each package contains 112 capsules, each containing 40 milligrams of enzalutamide. Bdenza belongs to a class of medications known as androgen receptor inhibitors and is primarily used in the treatment of prostate cancer.

Active Substance: The active substance in Bdenza is enzalutamide. Enzalutamide works by blocking the action of androgens (male hormones) such as testosterone from binding to and activating androgen receptors in prostate cancer cells. By inhibiting the androgen receptor signaling pathway, enzalutamide helps slow the growth and spread of prostate cancer cells.

Indications: Bdenza is indicated for the treatment of:

• Metastatic castration-resistant prostate cancer (mCRPC): It is used in adult men with metastatic castration-resistant prostate cancer who have previously received chemotherapy with docetaxel.
• Non-metastatic castration-resistant prostate cancer (nmCRPC): It is used in adult men with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Mechanism of Action:

• Enzalutamide is an androgen receptor inhibitor that works by competitively binding to the androgen receptor and preventing androgens such as testosterone from binding to and activating the receptor.
• By inhibiting androgen receptor signaling, enzalutamide blocks the growth-promoting effects of androgens on prostate cancer cells, leading to inhibition of tumor growth and spread.

Administration:

• Bdenza capsules are taken orally with water, usually once daily.
• The capsules should be swallowed whole and should not be crushed, chewed, or opened.
• It is recommended to take Bdenza capsules at the same time each day, with or without food.

Dosage:

• The recommended dosage of Bdenza is one 40-milligram capsule taken orally once daily.
• Treatment duration and dosage adjustments may be made based on the individual patient’s response to treatment and tolerability.

Monitoring:

• Patients taking Bdenza should be monitored regularly by their healthcare provider to assess treatment response and monitor for any signs of adverse effects or disease progression.
• Monitoring may include regular prostate-specific antigen (PSA) tests, imaging studies, and clinical assessments.

Side Effects: Common side effects of enzalutamide may include:

• Fatigue
• Hot flashes
• Hypertension (high blood pressure)
• Diarrhea
• Nausea
• Constipation
• Loss of appetite
• Weight loss
• Headache
• Muscle weakness

Precautions:

• Bdenza should be used with caution in patients with a history of seizures, as enzalutamide may increase the risk of seizure activity.
• It is important to inform the healthcare provider about all medications, supplements, and herbal products being taken, as enzalutamide may interact with certain medications.
• Women who are pregnant or breastfeeding should not handle or come into contact with Bdenza capsules due to the potential risk to the fetus or infant.

Consultation with Healthcare Professional:

• The use of Bdenza should be discussed with a healthcare professional, typically an oncologist or urologist.
• Patients should inform their healthcare provider about their medical history, existing health conditions, and any medications they are taking before starting treatment with enzalutamide.

Bdenza, manufactured by BDR Pharmaceuticals Int’l Pvt Ltd, is a medication indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men. Its use involves careful adherence to dosage and instructions for use, as well as regular monitoring by a healthcare provider to assess treatment response and monitor for any adverse effects or disease progression.